SCHEDULE: Viking Global Discloses 5.5% Stake in Oruka Therapeutics

Viking Global Investors and its affiliates have reported a 5.5% beneficial ownership stake in Oruka Therapeutics, Inc., totaling 2,666,690 shares.

Summary

• Viking Global Investors LP and its affiliated entities, along with executive committee members O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet, collectively reported beneficial ownership of 2,666,690 shares of Oruka Therapeutics, Inc. Common Stock.
• This ownership represents 5.5% of Oruka Therapeutics' outstanding Common Stock.
• The percentage is calculated based on 48,384,150 shares of Common Stock outstanding, which includes shares issued in a private placement that closed on September 19, 2025.
• The reporting persons hold shared voting and dispositive power over these shares.
• The acquisition of these securities was not for the purpose of changing or influencing the control of Oruka Therapeutics.

Sentiment

Score: 7

Explanation: The disclosure of a significant stake by a prominent institutional investor like Viking Global Investors is generally viewed positively, indicating confidence in the company. However, it's a passive investment disclosure, not an operational update, so the sentiment is moderately positive rather than strongly bullish.

Positives

• A significant institutional investor, Viking Global Investors, has taken a substantial stake in Oruka Therapeutics, indicating confidence in the company's future prospects.
• The 5.5% ownership by a reputable investment firm can enhance market visibility and potentially attract further institutional interest.

Risks

• No specific risks related to Oruka Therapeutics' operations or financial health are detailed, as this is a disclosure of ownership rather than an operational report.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Oruka Therapeutics' future performance or strategic direction, focusing solely on beneficial ownership disclosure.

Industry Context

In the biotechnology sector, significant institutional investments like Viking Global's 5.5% stake in Oruka Therapeutics can be a strong signal of confidence in a company's pipeline, technology, or market potential. Such investments often precede increased analyst coverage and broader investor interest, particularly for emerging biotech firms.

Stakeholder Impact

• **Shareholders**: Existing shareholders may view this as a positive signal, potentially leading to increased investor confidence and demand for the stock.
• **Potential Investors**: The presence of a major institutional investor could attract new investors, validating Oruka Therapeutics' investment thesis.
• **Company Management**: A significant institutional shareholder may bring increased scrutiny or influence, though the filing states the investment is not for control purposes.

Key Dates

Recommendation

The disclosure of a 5.5% stake by Viking Global Investors is a positive indicator, suggesting institutional confidence in Oruka Therapeutics. However, this filing is purely an ownership disclosure and does not provide new operational or financial performance data. While the institutional backing is favorable, without further fundamental updates on the company's progress, a 'hold' recommendation is prudent for existing investors, and 'buy' for new investors might be premature without deeper due diligence into Oruka's core business and financials beyond this ownership report.

Keywords

Oruka Therapeutics, Viking Global Investors, Institutional Investment, Beneficial Ownership, SEC Filing, Schedule 13G, Biotechnology, Common Stock, Equity Stake, Private Placement